Trials investigated one-third of the medicines that were indicated as a priority for pharmacokinetic research by the European Medicines Agency.
To examine this further, we investigated "one-third" samples (three oocytes from a third patient, patient 6, lysed together and divided into three equal volumes), which were run on the same assay as oocytes from patients 4 and 5 (Supplemental Table 2).
However, even in those relatively well educated cohorts investigated (about one third having university education in both countries), 20%- 30% reported oral impacts and dissatisfaction with oral health suggesting need for oral health care and treatment.
Based on our findings and combined with data from the literature it can be concluded that EGFR/HER2-neu directed molecular treatments could benefit and should be investigated in one fourth of all invasive epithelial ovarian cancers.
While other countries are eating most fish species found in their waters, the American fish buyer has to investigate each one first.
Over-expression of RUNX1 (AML1) was further investigated and in one third of the patients correlated with cytogenetic findings.
Two dosages of germ water were investigated: (1) one-third (33.33%) of total liquid in slurry, referred as partial germ water (treatments T3, T4, T7 in Table 1), (2) 100% of liquid in slurry, referred as full germ water (treatment T5 in Table 1) in the article.
It would therefore be very interesting to investigate the reasons why about one third of TKA patients can achieve good functional outcome, but two thirds have poor outcome.
Humphreys and colleagues [ 10] investigated neck pain in 180 patients: one third reported dizziness.
Hence, more than one third of the investigated biochemical activities displayed an uneven distribution with regards to protein size.
This may be one reason why confidence intervals for the number needed to treat were given in one third of the investigated articles only (time-to-event and binary data).
